Director Appointment

RNS Number : 1750A

OptiBiotix Health PLC

10 September 2018

 

OptiBiotix Health plc

("OptiBiotix")

Director Appointment

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high

cholesterol and diabetes, announces that, further to the previous announcement made on 6 August 2018 regarding the proposed appointment of Sean Christie as Non-Executive Director of the Company, the regulatory due diligence process has now been completed and the text below sets out the required disclosures.

Pursuant to Rule 17 and Schedule 2(g) of the AIM Rules for Companies, the following information is disclosed in respect of Michael Sean Christie (aged 60):

Current Appointments	Appointments in the last 5 years
ACCSYS Technologies Plc	Croda Enterprises Limited
Applied Graphene Materials Plc	Croda Europe Limited
Turner & Townsend Limited	Croda International Plc
	Croda Investments Limited
	Croda Investments No 2 Limited
	Croda JDH Limited
	Croda Overseas Holdings Limited
	Croda Polymers International Limited
	Croda World Traders Limited
	Eminate Limited
	Produce Investments Limited

For further information, please contact:

OptiBiotix Health plc		www.optibiotix.com
Stephen O'Hara, Chief Executive		Contact via Walbrook below
Cairn Financial Advisers LLP (NOMAD)		Tel: [phone]
Liam Murray / Jo Turner / Ludovico Lazzaretti
finnCap (Broker)		Tel: [phone]
Geoff Nash/ Scott Mathieson / Kate Bannatyne (Corporate Finance)
Camille Gochez (Corporate Broking)
Walbrook PR Ltd	Tel: [phone] or [e-mail]
Anna Dunphy		Mob: [phone]
Lianne Cawthorne		Mob: [phone]

About OptiBiotix - www.optibiotix.com 

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness. 

OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. 

 

END

 

 

BOAUGURGBUPRGCM